Log on / register
Feedback | Support | My details
Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients.
Markou N, Apostolakos H, Koumoudiou C, Athanasiou M, Koutsoukou A, Alamanos I, Gregorakos L
Crit Care 2003 Oct, 7:R78-83
[Full text] [PubMed] [Related articles] [Cited on BioMed Central]


printer friendly 
to  [Help]

BioMed Central articles that cite the above article:

1.


Research article    
Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections
Gounden R, Bamford C, van Zyl-Smit R, Cohen K, Maartens G
BMC Infectious Diseases 2009, 9:26 (9 March 2009)
 [Abstract] [Full text] [PDF] [PubMed] [Related articles]
2.


Research    
Toxicity of polymyxins: a systematic review of the evidence from old and recent studies
Falagas ME, Kasiakou SK
Critical Care 2006, 10:R27 (13 February 2006)
 [Abstract] [Full text] [PDF] [PubMed] [Related articles] [Cited on BioMed Central]
3.


Research article    
Toxicity after prolonged (more than four weeks) administration of intravenous colistin
Falagas ME, Rizos M, Bliziotis IA, Rellos K, Kasiakou SK, Michalopoulos A
BMC Infectious Diseases 2005, 5:1 (10 January 2005)
 [Abstract] [Full text] [PDF] [PubMed] [Related articles] [Cited on BioMed Central]

This article is also cited by a further 15 articles in PubMed Central


You can also check ISI Web of Science for additional citations (subscription required)
printer friendly 
to  [Help]
Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.